These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

293 related articles for article (PubMed ID: 37318642)

  • 1. Current perspectives on Vaxinia virus: an immuno-oncolytic vector in cancer therapy.
    Kaur SD; Singh AD; Kapoor DN
    Med Oncol; 2023 Jun; 40(7):205. PubMed ID: 37318642
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evolving Role of Oncolytic Virotherapy: Challenges and Prospects in Clinical Practice.
    Moaven O; W Mangieri C; A Stauffer J; Anastasiadis PZ; Borad MJ
    JCO Precis Oncol; 2021; 5():. PubMed ID: 34250386
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimization and preclinical design of genetically engineered viruses for human oncolytic therapy.
    Hiss DC; Fielding BC
    Expert Opin Biol Ther; 2012 Nov; 12(11):1427-47. PubMed ID: 22788715
    [TBL] [Abstract][Full Text] [Related]  

  • 4. History of how viruses can fight cancer: From the miraculous healings to the approval of oncolytic viruses.
    Bifulco M; Di Zazzo E; Napolitano F; Malfitano AM; Portella G
    Biochimie; 2023 Mar; 206():89-92. PubMed ID: 36273765
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of oncolytic virotherapy: from genetic modification to combination therapy.
    Lan Q; Xia S; Wang Q; Xu W; Huang H; Jiang S; Lu L
    Front Med; 2020 Apr; 14(2):160-184. PubMed ID: 32146606
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oncolytic virotherapy as promising immunotherapy against cancer: mechanisms of resistance to oncolytic viruses.
    Goradel NH; Alizadeh A; Hosseinzadeh S; Taghipour M; Ghesmati Z; Arashkia A; Negahdari B
    Future Oncol; 2022 Jan; 18(2):245-259. PubMed ID: 34821517
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The limiting factors of oncolytic virus immunotherapy and the approaches to overcome them.
    Hu PY; Fan XM; Zhang YN; Wang SB; Wan WJ; Pan HY; Mou XZ
    Appl Microbiol Biotechnol; 2020 Oct; 104(19):8231-8242. PubMed ID: 32816087
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Strategies to Develop Potent Oncolytic Viruses and Enhance Their Therapeutic Efficacy.
    Moaven O; Mangieri CW; Stauffer JA; Anastasiadis PZ; Borad MJ
    JCO Precis Oncol; 2021; 5():. PubMed ID: 34250395
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tutorial: design, production and testing of oncolytic viruses for cancer immunotherapy.
    Gujar S; Pol JG; Kumar V; Lizarralde-Guerrero M; Konda P; Kroemer G; Bell JC
    Nat Protoc; 2024 Sep; 19(9):2540-2570. PubMed ID: 38769145
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oncolytic Newcastle disease virus as a prospective anti-cancer therapy. A biologic agent with potential to break therapy resistance.
    Schirrmacher V
    Expert Opin Biol Ther; 2015; 15(12):1757-71. PubMed ID: 26436571
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oncolytic Virotherapy in Glioma Tumors.
    Rius-Rocabert S; García-Romero N; García A; Ayuso-Sacido A; Nistal-Villan E
    Int J Mol Sci; 2020 Oct; 21(20):. PubMed ID: 33066689
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunogenic cell death: The cornerstone of oncolytic viro-immunotherapy.
    Palanivelu L; Liu CH; Lin LT
    Front Immunol; 2022; 13():1038226. PubMed ID: 36755812
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dendritic cells and natural killer cells: The road to a successful oncolytic virotherapy.
    Ghasemi M; Abbasi L; Ghanbari Naeini L; Kokabian P; Nameh Goshay Fard N; Givtaj N
    Front Immunol; 2022; 13():950079. PubMed ID: 36703982
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oncolytic viruses and their application to cancer immunotherapy.
    Chiocca EA; Rabkin SD
    Cancer Immunol Res; 2014 Apr; 2(4):295-300. PubMed ID: 24764576
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Advances and potential pitfalls of oncolytic viruses expressing immunomodulatory transgene therapy for malignant gliomas.
    Zhang Q; Liu F
    Cell Death Dis; 2020 Jun; 11(6):485. PubMed ID: 32587256
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fighting Cancer with Viruses: Oncolytic Virus Therapy in China.
    Wei D; Xu J; Liu XY; Chen ZN; Bian H
    Hum Gene Ther; 2018 Feb; 29(2):151-159. PubMed ID: 29284308
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Exploiting diversity: genetic approaches to creating highly potent and efficacious oncolytic viruses.
    Bauzon M; Hermiston TW
    Curr Opin Mol Ther; 2008 Aug; 10(4):350-5. PubMed ID: 18683099
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oncolytic virotherapy for oral squamous cell carcinoma using replication-competent viruses.
    Saito K; Shirasawa H; Isegawa N; Shiiba M; Uzawa K; Tanzawa H
    Oral Oncol; 2009 Dec; 45(12):1021-7. PubMed ID: 19833547
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Approaches to Optimize Gene Therapy for the Treatment of Hematologic Malignancies: Overcoming the Obstacles.
    Jiang Y; Xia B; Zhang Y; Xu W
    Curr Gene Ther; 2017; 16(6):390-400. PubMed ID: 28215147
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oncolytic virotherapy.
    Russell SJ; Peng KW; Bell JC
    Nat Biotechnol; 2012 Jul; 30(7):658-70. PubMed ID: 22781695
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.